This study focuses on treating newborns with neonatal hypoxic-ischemic encephalopathy, a serious condition where the baby’s brain doesn’t receive enough oxygen and blood around the time of birth. The treatment being tested uses autologous cord blood stem cells, which are special cells collected from the baby’s own umbilical cord blood.

The study aims to determine if using these stem cells is safe and possible as a treatment option for newborns with brain injury caused by oxygen deprivation. The treatment involves giving the processed stem cells back to the baby through intravenous infusion, which means the cells are delivered directly into the bloodstream.

During the study, babies will receive their own cord blood cells that have been specially prepared as a medical treatment. The treatment is given alongside standard cooling therapy (therapeutic hypothermia) that these babies typically receive. Doctors will monitor the children’s development and check for any effects of the treatment for up to two years after the procedure.